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Abstract It was previously reported that 8701-BC breast
cancer cells express the gene for parathyroid hormone-related
peptide (PTHrP) and its cognate receptor (PTHrP-R), and
release immunoreactive PTHrP in the extracellular medium; it
was also found that PTHrP, in turn, exerts a role on the
proliferative and invasive behavior in vitro of the same cell line.
On the other hand, evidence has been produced that adhesion of
8701-BC cells onto different collagen substrates influences in
various ways a number of phenotypic expressions, such as cell
growth, motility, invasion of reconstituted basement membrane
and production of lytic enzymes of the extracellular matrix
(ECM). In light of these previous data, we have examined
whether substrates of either reconstituted basement membrane or
representative collagen components of the breast tumor stroma
(type I, V and OF/LB) might (i) regulate the PTHrP promoter
usage and mRNA splicing patterns, (ii) modulate quantitatively
the extracellular release of immunoreactive PTHrP (iPTHrP),
and (iii) affect the expression of PTHrP-R. The results obtained
give evidence that (i) 8701-BC cells are able to utilize different
start sites and mRNA splicing patterns for PTHrP transcription;
(ii) ‘structural’ components of the stroma, such as collagens, are
by themselves capable of controlling both the expression pattern
of the PTHrP gene and the extent of extracellular release of
iPTHrP, and (iii) PTHrP-R expression can be up- or down-
regulated in response to the ECM substrate present. These data
demonstrate that PTHrP and PTHrP-R expression by 8701-BC
neoplastic cells can be modulated by ECM molecules, indirectly
supporting the active participation of stromal collagen composi-
tion in the regulation of PTHrP-controlled circuits which may
play a role in carcinogenesis.
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1. Introduction
Previous ultrastructural and biochemical investigations
have shown that in cases of ductal in¢ltrating carcinoma
(DIC), a highly invasive tumor histotype of the human mam-
mary gland, the desmoplastic stroma, apart from displaying
marked modi¢cations in its architecture, undergoes conspicu-
ous quantitative and qualitative changes in its collagen com-
position. These changes chie£y consist of the enhanced depo-
sition of collagen type V and the re-appearance of OF/LB
(onco-fetal/laminin-binding) collagen. The latter is an em-
bryo-fetal collagen species absent in normal adult tissues but
detectable also in human umbilical cord and colon carcinoma
tissues, which is composed of three K1(I)-sized chains one of
which displaying an unusually acidic pI [1^4]. In addition,
when cell^collagen interplays were studied using the 8701-
BC breast cancer cell line [5] as an in vitro model of neoplastic
cell population from primary DIC, evidence was produced
that adhesion of cells onto di¡erent collagen substrates in£u-
enced in varying ways a number of phenotypic expressions
related to neoplastic progression in vivo, such as cell growth,
motility, invasion of reconstituted basement membrane and
production of lytic enzymes of the extracellular matrix
(ECM) [6^10].
We have recently shown that also the production of para-
thyroid hormone-related peptide (PTHrP) by breast cancer
cells can be conceivably considered one of the key elements
instrumental in promoting carcinogenesis [11,12]. PTHrP is
the product of a gene exhibiting a complex organization in
humans, with three transcriptional start sites, i.e. two TATA
boxes (P1 and P3) and a GC-rich region (P2), and nine exons
undergoing alternative splicing and producing mRNA var-
iants with likely di¡erential spatio-temporal expressions. The
deduced encoded polypeptides, of either 139, 141 or 173 ami-
no acids, display sequence homology with PTH at the extreme
N-terminus which allows the binding to the same G protein-
linked receptor (PTHrP-R). In recent years, evidence was
brought that PTHrP may be a polyhormone undergoing pro-
teolytic processing, possibly tissue-speci¢c, into several smaller
bioactive forms, some of which have been either immunode-
tected or isolated from conditioned media of normal and neo-
plastic cells. The polyproteic and almost ubiquitous nature of
PTHrP has therefore led to the concept that, apart from its
classically recognized PTH-like role played in establishing the
humoral hypercalcemia of malignancy, discrete fragments of
this protein may function as local autocrine/paracrine modu-
lators mediating growth factor-like roles through the PTHrP-
R and other still unknown receptor(s) (see [13] for a review).
Interestingly, the PTHrP gene has been described as a down-
stream target for ras and src and an upstream element of the
Bcl-2 and c-fos signalling pathways, thus supporting its in-
volvement in the control of cell proliferation, di¡erentiation
and survival [14^16]. In addition, PTHrP-R expression by
bone cells has been found to be down-regulated in the pres-
ence of ECM, suggesting a role of the latter in the modulation
of PTHrP/PTHrP-R interactions [17].
It was previously reported that 8701-BC cells express the
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genes for PTHrP and its cognate receptor and release immu-
noreactive PTHrP (iPTHrP) fragments in the extracellular
medium [11,12,18]. In addition, PTHrP 1^34, 67^86 and, to
a minor extent, 107^139 have been described as anti-mitogenic
but invasion-promoting for the same cell line [11]. The present
study was designed to further expand our knowledge on tu-
mor cell^ECM interactions in vitro, by examining whether
substrates made of either reconstituted basement membrane
components or selected collagen species present in DIC stro-
ma (i.e. type I, V or OF/LB) which markedly alter cell behav-
ior, might (i) modulate quantitatively the extracellular release
of iPTHrP, (ii) regulate the PTHrP promoter usage and
mRNA splicing patterns, and (iii) a¡ect the expression of
PTHrP-R.
2. Materials and methods
2.1. Cell cultures
Collagen types I and V were purchased from Sigma (St. Louis, MO,
USA). OF/LB collagen was extracted from colon cancer tissue as
previously described [3,4] and the purity of the preparation was
checked by 2D-polyacrylamide gel electrophoresis (2D-PAGE) before
utilization (Fig. 1). Collagens were dissolved in 0.5 M acetic acid,
sterilized with chloroform as reported in [7], plated in 25 cm2 £asks
at a concentration of 10 Wg/cm2 for 2 days and exhaustively neutral-
ized with phosphate bu¡ered saline just before cell culturing. Matrigel,
purchased from Collaborative Res. (Bedford, MA, USA), was diluted
to a concentration of 250 Wg/ml and 1 ml was plated in 25 cm2 £asks
and allowed to gel overnight.
8701-BC cells [5] were routinely cultured in RPMI 1640 medium
(Gibco, Paisley, UK), supplemented with 10% fetal calf serum (Gibco)
and antibiotics. Cells were detached with 0.1% EDTA, plated in sub-
strate-coated £asks at a concentration of 106/£ask in serum-free con-
ditions and allowed to grow for 2 days. At the end of the assay, the
conditioned medium (CM) was collected, centrifuged at low speed to
discard cell debris, lyophilized and stored at 320‡ until used. Cell
number was determined by counting with a hemocytometer.
2.2. Midregional iPTHrP radioimmunoassay (RIA)
For this assay, 100 Wl goat antiserum (1:8000) raised against amino
acids 53^84 and 100 Wl reconstituted CM were incubated under non-
equilibrium conditions. Synthetic human PTHrP 1^86 (Bissendorf
Biochem., Hannover, Germany) was used as standard and for tracer
preparation [19]. The assay had a detection limit of 5 pmol/l. The
results of RIAs were normalized to actual cell number and expressed
as pmol iPTHrP/106 cells.
2.3. RNA extraction, cDNA synthesis and polymerase chain reaction
(PCR)
Total RNA from 8701-BC cells cultured on the di¡erent substrates
was isolated with TRI reagent (Roche, Mannheim, Germany). Ali-
quots of 5 Wg of RNA from at least two di¡erent preparations were
reverse-transcribed using the SuperScript kit (Gibco, Gaithersburg,
MD, USA) in the presence of random hexamers, according to the
manufacturer’s instructions. The semi-quantitative PCR ampli¢cation
was carried out as described by Brandt et al. [20] in an UNO Thermo-
block (Biometra, Go«ttingen, Germany) using 100 ng of RNA/cDNA
diluted with 0.5 mM dNTPs, 0.5 WM of each primer, 1 unit of rTaq
DNA polymerase (Pharmacia, Uppsala, Sweden) and 0.5 WCi
[32P]dCTP (ICN, Thame, UK). The thermal cycle used was a denatu-
ration step of 96‡C for 3 min and a 5 min ‘ramp’ time to the annealing
temperature for 2 min, followed by 30 cycles of 95‡C for 15 s, the
annealing temperature for 30 s and 72‡C for 45 s. GAPDH was
ampli¢ed in parallel and used as inter-sample control; radiolabelled
ampli¢cation products of actin, GAPDH, transforming growth factor
L1 (TGFL1) and urokinase-plasminogen activator (uPa) were em-
ployed as size markers. The primers used and the predicted size of
their ampli¢cation products are listed in Table 1 along with related
references. PCR products were analyzed by 8% non-denaturing poly-
acrylamide gel electrophoresis in a Mini-Protean II apparatus (Bio-
Rad, Richmond, CA, USA) and visualized after exposure of the dried
gels to Kodak BioMax ¢lms with intensifying screen at 380‡C. Sig-
maGel 1.0 software (Jandel Scienti¢c, USA) was utilized for the size
evaluation of the electrophoretic bands.
Fig. 1. 2D-PAGE analysis of OF/LB collagen used in the present
study. Collagen was extracted from a biopsy fragment of the tumor
core and of the adjacent colonic mucosa by mildly acidic pepsin di-
gestion and OF/LB collagen fractionated by several cycles of di¡er-
ential precipitation at pH 7.2 [3,4]. The preparation obtained from
the neoplastic tissue (A), subsequently used for the biological assays
described, shows the presence of the characteristic acidic chain of
OF/LB collagen appearing as a twin spot (a), and of the two other
components of this collagen species migrating as K1(III)- and K1(I)-
like chains (b and c). The component present in band d displays the
migratory behavior of the K2(I) collagen chain, although recent bio-
chemical evidence has demonstrated the occurrence of sequence
overmodi¢cations in tumoral K2(I) collagen chains with respect to
the ‘regular’ counterpart [38]. As expected, no component of OF/LB
collagen can be observed in the preparation from the adjacent ‘nor-
mal’ tissue (B), used as a control for collagen extraction. First di-
mension (1D): non-equilibrium pH gradient gel electrophoresis
(NEPHGE); second dimension (2D): SDS-PAGE. Coomassie stain.
Fig. 2. E¡ect of the di¡erent ECM substrates on the proliferative
behavior of 8701-BC cells 48 h after plating. The vertical bars indi-
cate the S.E.M.
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2.4. Statistics
Data are presented as mean þ S.E.M. of either three (for prolifer-
ation) or six (for iPTHrP dosage) di¡erent experiments; a software-
assisted Student’s t-test was performed (SigmaStat v.2, Jandel, USA)
and P6 0.05 was taken as the minimal level of statistical signi¢cance.
3. Results
When Matrigel, type I, V or OF/LB collagen are used as
substrate cultures, 8701-BC cells undergo modi¢cations of
their proliferative behavior. In particular, as shown in Fig.
2, OF/LB collagen substrate and Matrigel are equally strong
promoters of 8701-BC cell growth (average of about +89%
and +67% with respect to the initial cell concentration;
Ps 0.05 between the two sets of data) in opposition to type
I (333.3 þ 3% versus OF/LB collagen; P = 0.019) and, mainly,
to type V collagen substrates (359.8 þ 1.5% versus OF/LB
collagen; P6 0.001).
Therefore, we examined whether the di¡erent substrates
were also able to modulate the production of iPTHrP, sub-
jecting cell CMs to a RIA speci¢c for a mid-regional domain
of PTHrP which was proven to give reliable results with the
8701-BC cell line [11]. The data reported in Fig. 3 indicate
that the release of PTHrP can be strongly in£uenced by ad-
hesion onto di¡erent substrates. In particular, after normal-
ization of the data to the actual cell numbers, variable in the
di¡erent culture conditions as already reported, OF/LB colla-
gen and Matrigel are found to be the most e⁄cient inducers of
PTHrP secretion (Ps 0.05 between the two sets of data).
Table 1
Sequence of primers used for PCR ampli¢cation
Transcript detected Oligonucleotides Product size (bp) Reference
PTHrP P1 5P-AGGTACCTGCTTTCTAATA-3P 739, 646, 406 [21]
5P-TGCGATCAGATGGTGAAGGA-3P
PTHrP P2 5P-TTCTCCGGCAGGTTTG-3P 468 [21]
5P-TGCGATCAGATGGTGAAGGA-3P
PTHrP P3 5P-GTTGGAGTAGCCGGTTGCTA-3P 242 [21]
5P-TGCGATCAGATGGTGAAGGA-3P
PTHrP 1^139 5P-AAACGGCGAACTCGCTCT-3P 134 [22]
5P-AGGCTACGGGCCAGAGAAG-3P
PTHrP 1^141 5P-AAACGGCGAACTCGCTCT-3P 145 [22]
5P-TGTCCTTGGAAGGTCTCTG-3P
PTHrP 1^173 5P-AAACGGCGAACTCGCTCT-3P 242 [22]
5P-CCTATCTGTAGCAGAGTCAA-3P
PTHrP-R 5P-AGGAACAGATCTTCCTGCTGCA-3P 571 [12]
5P-TGCATGTGGATGTAGTTGCGCGT-3P
GAPDH 5P-CATGGAGAAGGCTGGGGCTC-3P 414 [21]
5P-CACTGACACGTTGGCAGTGG-3P
L-Actin 5P-GTGGGGCGCCCCAGGCACCA-3P 548 [18]
5P-CTCCTTAATGTCACGCACGATTTC-3P
TGFL1 5P-GCCCTGGACACCAACTATTGC-3P 336 [18]
5P-GCTGCACTTGCAGGAGCGCAC-3P
uPa 5P-ATGAGAGCCCTGGCGCGCCTG-3P 198 [18]
5P-TTTTTGAATCTATTTCACAGTGCTGCCCTCCGAATTTT-3P
Fig. 3. E¡ect of the di¡erent ECM substrates on iPTHrP produc-
tion by 8701-BC cells 48 h after plating. The vertical bars indicate
the S.E.M.
Fig. 4. Panel of semi-quantitative PCR analyses of PTHrP promoter
usage and splicing pattern, and of PTHrP-R expression, representa-
tive of triplicate assays. The ampli¢cation was carried out in the
presence of [32P]dCTP and the products were separated by 6%
PAGE in parallel with labelled controls (not shown) and autoradio-
graphed at di¡erent exposure times in order to optimize the visibil-
ity of all the bands. GAPDH was used as inter-sample loading con-
trol.
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Conversely, the iPTHrP amount decreases in the CM of cells
cultured on type V (319.8 þ 2.7% versus OF/LB collagen;
P = 0.005) and, more dramatically, type I collagen substrate,
the latter being responsible for a massive drop of iPTHrP in
the extracellular milieu (353 þ 2% versus OF/LB collagen;
P6 0.005).
Subsequently, we analyzed PTHrP promoter usage and
mRNA splicing patterns in the presence of the various culture
substrates. As shown in Fig. 4, 8701-BC cells are able to
utilize each of the three di¡erent transcriptional start sites
and the three 3P splicing pathways with di¡erent arrays in
the presence of the substrates examined. Noteworthy, the
unique size of the ampli¢cation product in the presence of
P1-speci¢c primers is indicative of the generation of exon I-
III-V-VI isoform only, and the use of the P3 initiation site
appears to be widespread whilst that of P1 and P2 is more
restricted, in accordance with [21]. In particular, in the pres-
ence of type I collagen all the promoters were used with a
P3sP2sP1 pattern; no other substrate elicited the usage of
the GC-rich promoter since in the presence of type V and OF/
LB collagen only P1- and P3-speci¢c products were evident
(P3sP1 for type V collagen and P1sP3 for OF/LB colla-
gen). When cells were seeded onto Matrigel, only the down-
stream TATA box was transcriptionally active. Concerning
the PTHrP species, the 1^139 variant was present in all the
cDNA preparations and was the only species synthesized by
cells onto type I collagen substrate. Moreover, the 1^173 iso-
form-speci¢c PCR product was found in all but type I colla-
gen-derived cDNA preparation and the 1^141 isoform-speci¢c
PCR product only in type V collagen-derived samples and in
smaller amount than the other two species. Table 2 reports the
potential mRNA species arising from alternative splicing in
response to 8701-BC cell culturing on the di¡erent substrates
in light of both the present results and the organization of the
human PTHrP gene [23].
Further, the results concerning the expression of PTHrP-R
indicated its up-regulation in cells plated onto type V collagen
mainly and, to a lesser degree, type I collagen compared to
cells grown on Matrigel and OF/LB collagen, in which no
ampli¢cation signal was detectable, at least under the exper-
imental conditions used.
4. Discussion
It is widely recognized that ECM, due to its complex and
varying nature, may bear multiple instructive signals and elicit
a wide range of dissimilar cell responses, which are of primary
relevance during development, di¡erentiation and cancer and
whose molecular mechanisms are still mostly unknown.
PTHrP expression is one of those biological activities which
has been extensively studied in in vivo and in vitro systems
because of its massive involvement in several normal and neo-
plastic developmental processes (e.g. [23^27]). Moreover,
Behrendtsen et al. [28] have shown that PTHrP produced
during some di¡erentiation stages of the mouse embryo is
able to modify integrin expression and function and the
related cell response to extracellular ligands, thus actively
cooperating to drive cell^ECM interplays.
In the mammary gland, PTHrP is expressed in both the
resting and the lactation phase albeit to di¡erent extents [29]
and appears to in£uence the state of organ proliferation and
di¡erentiation; in fact, PTHrP oversecretion obtained by
transgene technology has been proven to inhibit ductal elon-
gation and branching [30]. Ferrari et al. [31] and Sebag et al.
[32] have demonstrated that certain growth factors and hor-
mones, e.g. TGFL, IGF-I, EGF, prolactin, are capable of
modifying the rate of PTHrP production by normal human
mammary epithelial cells in vitro.
We have already demonstrated the in vitro anti-prolifera-
tive and pro-invasive e¡ect exerted on the carcinoma cell line
8701-BC and some derived clones by PTHrP [11,12], which
has been therefore regarded also as one of the key elements
potentially involved in mammary tumorigenesis in vivo.
Nonetheless, the regulation of PTHrP and PTHrP-R expres-
sion and iPTHrP secretion by breast cancer cells has been
poorly investigated, the unique data being those regarding
the e¡ect of phorbol ester, steroid hormones and anti-estro-
gens on KPL-3C and MCF7 cell lines [33^35].
To the best of our knowledge, here we report the ¢rst evi-
dence that: (i) 8701-BC cells are potentially able to utilize
di¡erent start sites and mRNA splicing patterns for PTHrP
transcription; (ii) extracellular macromolecules of the stroma,
even in the absence of biologically active soluble factors added
to cell medium, are by themselves capable of controlling both
the expression pattern of PTHrP gene and the extent of ex-
tracellular release of PTHrP by the same cell line; and (iii)
PTHrP-R expression can be up- or down-regulated by the
ECM substrate present. The last two points further support
our hypothesis of the existence of diverse binding activities for
ECM molecules on 8701-BC cell surface ([36], and work in
progress). Interestingly, only one out of the four substrates
tested induced P2 expression: this ¢nding has a twofold sig-
ni¢cance since it strengthens the principle of ECM-driven cell
modulation, and also con¢rms previous data by Southby et al.
[21] on the scarcer utilization of the P2 (and P1) than the P3
site, which we could explain on the basis of the requirement of
select ligands bound to cell surface.
An intriguing biological observation arising from the
present study is the apparent correlation between the powerful
down-regulation of PTHrP-R expression and the active pro-
motion of cell proliferation operated by OF/LB collagen and
Matrigel substrates, in opposition to type I and, mainly, type
V collagen substrates. We have previously reported that the
PTHrP 1^34 fragment is able to restrain the growth of the
Table 2
(Top) Structure of the human PTHrP gene (¢lled boxes = coding se-
quences, open boxes = 5P- and 3P-untranslated regions [23]) and (bot-
tom) synopsis of potential mRNA species synthesized by 8701-BC
cells onto the di¡erent substrates, as evinced by PCR data
Type I collagen Ia-Ic-III-IV-V Type V collagen Ia-Ic-III-IV-V
Ic-II-IC-V Ia-Ic-III-IV-VI
II-III-IV-V Ia-Ic-III-IV-VII
II-III-IV-V
II-III-IV-VI
II-III-IV-VII
OF/LB collagen Ia-Ic-III-IV-V Matrigel II-III-IV-V
Ia-Ic-III-IV-VI II-III-IV-VI
II-III-IV-V
II-III-IV-VI
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8701-BC cell line and of the derived clonal sublines expressing
PTHrP-R [11,12]. It can therefore be hypothesized that a
growth-restraining behavior, such as that imparted by type
V collagen to 8701-BC cells, could be more seemingly related
to the ability to bind N-terminal PTHrP and install an auto-
crine e¡ect than to the actual amount of iPTHrP released,
which cannot be correlated with cell proliferation. Interest-
ingly, recent data (Pucci-Minafra et al., submitted) have re-
vealed the apoptosis-promoting e¡ect of collagen type V on a
conspicuous fraction of 8701-BC cells and, therefore, it will be
worthwhile to examine if the observed modi¢cations on
PTHrP and PTHrP-R expression and production may be
related to the gene activation cascade of the death program.
On the other hand, whether the substrate-dependent modula-
tion of the expression of the di¡erent species of transcripts or
protein isoform may have some biological signi¢cance in our
model system remains to be elucidated.
In conclusion, we have produced evidence that not only the
proliferative behavior but also the expression of the PTHrP/
PTHrP-R pair by a DIC cell line is modulated by stromal
components and that the two phenotypic aspect are possibly
associated. Although caution must be exercised in extrapola-
tion of in vitro results to the in vivo situation, the data ob-
tained further support the postulate that local ECM compo-
sition may be a crucial regulatory parameter for malignant
ingrowth. The present ¢ndings are in fact consistent with
the hypothesis that both permissive and inhibitory pathways
may be present in the basal lamina and stromal compartments
of the a¡ected mammary tissue governing regulation of
PTHrP and PTHrP-R expression and production to di¡erent
degrees. These pathways, subjected to a dynamic and zonal
turn-over of synthetic and degradative events (e.g. [37]), con-
ceivably participate in feeding or restraining the autocrine/
paracrine circuits which are likely to exist between PTHrP
and sensitive breast cancer (and other) cells; the resulting
di¡erential e¡ects on cell behavior might contribute in concert
with other microenvironmental signals to control tumor
growth and di¡erentiation.
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